Biogen Inc. (BIIB)
NASDAQ: BIIB · Real-Time Price · USD
130.36
-1.50 (-1.14%)
At close: Jun 5, 2025, 4:00 PM
130.21
-0.15 (-0.12%)
After-hours: Jun 5, 2025, 4:39 PM EDT
Biogen Employees
Biogen had 7,605 employees as of December 31, 2024. The number of employees increased by 35 or 0.46% compared to the previous year.
Employees
7,605
Change (1Y)
35
Growth (1Y)
0.46%
Revenue / Employee
n/a
Profits / Employee
n/a
Market Cap
19.10B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 7,605 | 35 | 0.46% |
Dec 31, 2023 | 7,570 | -1,155 | -13.24% |
Dec 31, 2022 | 8,725 | -885 | -9.21% |
Dec 31, 2021 | 9,610 | 510 | 5.60% |
Dec 31, 2020 | 9,100 | 1,700 | 22.97% |
Dec 31, 2019 | 7,400 | -400 | -5.13% |
Dec 31, 2018 | 7,800 | 500 | 6.85% |
Dec 31, 2017 | 7,300 | -100 | -1.35% |
Dec 31, 2016 | 7,400 | 50 | 0.68% |
Dec 31, 2015 | 7,350 | -200 | -2.65% |
Dec 31, 2014 | 7,550 | 700 | 10.22% |
Dec 31, 2013 | 6,850 | 900 | 15.13% |
Dec 31, 2012 | 5,950 | 950 | 19.00% |
Dec 31, 2011 | 5,000 | 150 | 3.09% |
Dec 31, 2010 | 4,850 | 100 | 2.11% |
Dec 31, 2009 | 4,750 | 50 | 1.06% |
Dec 31, 2008 | 4,700 | 400 | 9.30% |
Dec 31, 2007 | 4,300 | 550 | 14.67% |
Dec 31, 2006 | 3,750 | 410 | 12.28% |
Dec 31, 2005 | 3,340 | -926 | -21.71% |
Dec 31, 2004 | 4,266 | 539 | 14.46% |
Feb 20, 2004 | 3,727 | 2,732 | 274.57% |
Jan 31, 2003 | 995 | 303 | 43.79% |
Jan 31, 2002 | 692 | 199 | 40.37% |
Jan 31, 2001 | 493 | 86 | 21.13% |
Jan 31, 2000 | 407 | 42 | 11.51% |
Jan 31, 1999 | 365 | 26 | 7.67% |
Dec 31, 1997 | 339 | 71 | 26.49% |
Dec 31, 1996 | 268 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
BIIB News
- 2 days ago - Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors - GlobeNewsWire
- 9 days ago - Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies - GlobeNewsWire
- 24 days ago - Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet - Seeking Alpha
- 24 days ago - Jeito Capital Strengthens Leadership for Next Chapter of Growth: Mehdi Ainouche Promoted to Partner, Julien Elric to Senior Principal - GlobeNewsWire
- 5 weeks ago - Biogen Inc. (BIIB) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Biogen beats quarterly profit estimates on strong demand for rare disease drugs - Reuters
- 5 weeks ago - Biogen: Is This A Value Trap, Or Is The Great Turnaround Imminent? - Seeking Alpha
- 7 weeks ago - Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer's Disease to be Authorized in the European Union - GlobeNewsWire